

Application No.: 10/524,395

Docket No.: ALXN-P01-000  
**RECEIVED  
 CENTRAL FAX CENTER**

**OCT 17 2008**

**AMENDMENTS TO THE CLAIMS**

This listing of the claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (Currently amended) A method for treating a subject suffering from an infection with a yeast or fungus ~~exposed to a microorganism~~ that binds to DC-SIGN, said method comprising administering to a subject in need thereof an antibody that binds DC-SIGN in an amount effective to inhibit the binding of said yeast or fungus ~~microorganism~~ to DC-SIGN.

2. (Previously presented) The method of claim 1 wherein said antibody inhibits binding of  $\beta$ -1,2-oligomannoside to DC-SIGN.

3-4. (Cancelled)

5. (Currently amended) The method of claim 1 wherein said yeast ~~microorganism~~ is *Candida*.

6. (Currently amended) The method of claim 5 wherein said yeast ~~microorganism~~ is the species *Candida albicans*, *Candida dubliniensis* or *Candida glabrata*.

7. (Currently amended) The method of claim 1 wherein said fungus ~~microorganism~~ is *Aspergillus fumigatus*.

8. (Original) The method of claim 1 wherein said subject is a human.

9. (Canceled)

10. (Currently amended) The method of claim 1 wherein said antibody is ~~selected from the group consisting of AZN-D1, AZN-D2 and AZN-D3.~~ the antibody produced by the hybridoma

Application No.: 10/524,395

Docket No.: ALXN-P01-093

cell line deposited as ECACC accession number 99040818, the antibody produced by the hybridoma cell line deposited as ECACC accession number 99040819, or the antibody produced by the hybridoma cell line deposited as ECACC accession number 03071801.

11. (Currently amended) The method of claim 1 wherein two or more antibodies that inhibit binding of the yeast or fungus ~~microorganism~~ to DC-SIGN are administered in combination.

12. (Currently amended) A method of inhibiting infection by a yeast or fungus in a subject comprising administering to a subject in need thereof an antibody that binds DC-SIGN wherein said antibody at least partially inhibits binding of an infection-causing yeast or fungus ~~microorganism~~ to DC-SIGN on dendritic cells.

13-15. (Canceled)

16. (Previously presented) The method of claim 12 wherein more than one antibody that inhibits binding is administered.

17-32. (Canceled)

33. (New) The method of claim 12 wherein said antibody inhibits binding of  $\beta$ -1,2-oligomannoside to DC-SIGN.

34. (New) The method of claim 12 wherein said yeast is *Candida*.

35. (New) The method of claim 34 wherein said yeast is the species *Candida albicans*, *Candida dubliniensis* or *Candida glabrata*.

36. (New) The method of claim 12 wherein said fungus is *Aspergillus fumigatus*.

37. (New) The method of claim 12 wherein said subject is a human.

Application No.: 10/524,395

Docket No.: ALXN-P01-093

38. (New) The method of claim 12 wherein said antibody is the antibody produced by the hybridoma cell line deposited as ECACC accession number 99040818, the antibody produced by the hybridoma cell line deposited as ECACC accession number 99040819, or the antibody produced by the hybridoma cell line deposited as ECACC accession number 03071801.